

biotech companies tackling today’s biggest challenges.
Rethinking IVF: New Biotechnologies for Better Outcomes
From eggs retrieved to embryos available for transfer, attrition is one of the central challenges in IVF. Where do these losses happen, what drives them, and where could new biotechnologies make a meaningful difference?
Rejoovenate Bio and Oterus Bio are tackling different stages of this attrition funnel, translating advances in reproductive science into new technologies with a shared ambition: helping more patients achieve successful pregnancies.
We’ll explore:
The bottlenecks along the IVF journey—and the challenges clinicians and embryologists see every day.
Emerging biotech approaches to improving egg and embryo competence.
What it takes to turn promising science into technologies that deliver meaningful benefits for fertility patients.
Whether you’re a clinician, scientist, founder, investor, or simply interested in the future of fertility care, come exchange ideas and meet others working toward better IVF outcomes.
Event rundown
4:00–4:45 PM: Arrival and mingling
4:45–5:30 PM: Panel discussion
5:30–5:45 PM: Audience Q&A
5:45–7:00 PM: Networking and continued conversation
Hosted by
Rejoovenate Bio: San Francisco-based company developing technologies to improve egg quality by targeting the aging follicular environment. With an initial focus on improving IVF outcomes, the company’s long-term mission is to extend the female reproductive window.
Oterus Biosystems: San Diego-based company developing EmbryoNest, a biomimetic culture plate whose engineered surface mimics the female reproductive tract, replacing the flat plastic embryos have been grown on since 1978. Its first goal is to help IVF clinics get more transfer-quality embryos from each cycle, with no new equipment or retraining. Its long-term mission is to help more families get a successful pregnancy in fewer cycles.
MBC BioLabs: San Francisco Bay Area biotech incubator with sites in San Francisco and San Carlos. It provides lab space and operational support for early-stage biotech companies. Startups can rent anything from a single bench to a private lab, with shared equipment and operations support included, so they can start research without building their own facilities. Founded in 2013, MBC BioLabs has since helped launch hundreds of life science companies.
biotech companies tackling today’s biggest challenges.